UnitedHealth (UNH) Covers Shield Blood Test for Colon Cancer Screening

UnitedHealth Group (NYSE:UNH) has become the first major commercial insurer to cover Guardant Health's Shield blood test for early colorectal cancer screening. The new coverage applies to eligible adults aged 45 and older, expanding access to a blood-based alternative to traditional screening methods.

The Product

The Shield test is a simple blood test that detects tumor DNA in the blood, enabling early detection of colorectal cancer. It is less invasive than colonoscopy, which may increase screening compliance rates.

Pricing and Availability

UnitedHealth has not disclosed pricing details. Coverage is available for eligible members aged 45 and older, according to company policies.

Competition

The Shield test competes with other blood tests like Epi proColon, as well as traditional colonoscopy and stool tests. UnitedHealth's decision may pressure other insurers to follow suit.

Potential Impact on the Company

This move strengthens UnitedHealth's position as an innovator in access to emerging screening tools. It could lead to an increase in covered screenings, potentially reducing late-stage cancer treatment costs in the long run. The stock last closed at $417.99.